Cilostazol for Secondary Prevention of Stroke and Cognitive Decline | Zendy

Caroline McHutchison | Zendy; Gordon W. Blair | Zendy; Jason P. Appleton | Zendy; Francesca M. Chappell | Zendy; Fergus Doubal | Zendy; Philip M. Bath | Zendy; Joanna M. Wardlaw | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cilostazol for Secondary Prevention of Stroke and Cognitive Decline

Author(s) -

Caroline McHutchison,

Gordon W. Blair,

Jason P. Appleton,

Francesca M. Chappell,

Fergus Doubal,

Philip M. Bath,

Joanna M. Wardlaw

Publication year - 2020

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.120.029454

Subject(s) - medicine , cilostazol , stroke (engine) , aspirin , adverse effect , randomized controlled trial , odds ratio , placebo , clopidogrel , pathology , mechanical engineering , alternative medicine , engineering

Cilostazol, a phosphodiesterase 3' inhibitor, is used in Asia-Pacific countries for stroke prevention, but rarely used elsewhere. In addition to weak antiplatelet effects, it stabilizes endothelium, aids myelin repair and astrocyte-neuron energy transfer in laboratory models, effects that may be beneficial in preventing small vessel disease progression.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research